The Clinical Significance and Risk Factors of Anti-Platelet Factor 4/heparin Antibody on Maintenance Hemodialysis Patients: A Two-Year Prospective Follow-up

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zhao, Delong ^a   Sun, Xuefeng ^a   Yao, Li ^b   Lin, Hongli ^c   Li, Jijun ^a   Zhao, Jiuyang ^c   Zhang, Zhimin ^d   Lun, Lide ^e   Zhang, Jianrong ^f   Li, Mingxu ^g   Huang, Qi ^a   Yang, Yang ^a   Jiang, Shimin ^a   Wang, Yong ^a   Zhu, Hanyu ^a   Chen, Xiangmei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d General Hospital of Headquarters of the General Staff   (China)

^e AIR FORCE GENERAL HOSPITAL   (China)

^f Army Police General Hospital   (China)

^g General Hospital of Navy   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PLATELET FACTOR 4 HEPARIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; HEPARIN; THROMBOCYTE FACTOR 4;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BLEEDING; CHINA; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; BLOOD; CLINICAL TRIAL; HEMORRHAGE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 84876963751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062239     Document Type: Article

References (43)

1. Shen JI, Winkelmayer WC, (2012) Use and Safety of Unfractionated Heparin for Anticoagulation During Maintenance Hemodialysis. American Journal of Kidney Diseases 60: 473-486.
2. Aster RH, (1999) Drug-induced immune thrombocytopenia: An overview of pathogenesis. Seminars in Hematology 36: 2-6.
3. Haase M, Bellomo I, Rocktaeschel J, Ziemer S, Kiesewetter H, et al. (2005) Use of fondaparinux (ARIXTRA((R))) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrology Dialysis Transplantation 20: 444-446.
4. Warkentin TE, (2004) An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30: 273-283.
5. Hirsh J, Heddle N, Kelton JG, (2004) Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164: 361-369.
6. Warkentin TE, Greinacher A, Koster A, Lincoff AM, (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 340S-380S.
7. Kato S, Takahashi K, Ayabe K, Samad R, Fukaya E, et al. (2011) Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. Br J Haematol 154: 373-377.
8. O'Shea SI, Sands JJ, Nudo SA, Ortel TL, (2002) Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 69: 72-73.
9. Pena de la Vega L, Miller RS, Benda MM, Grill DE, Johnson MG, et al. (2005) Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 80: 995-1000.
10. Asmis LM, Segal JB, Plantinga LC, Fink NE, Kerman JS, et al. (2008) Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 100: 498-504.
11. Matsuo T, Kobayashi H, Matsuo M, Wanaka K, Nakamoto H, et al. (2006) Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb 35: 445-450.
12. Hutchison CA, Dasgupta I, (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22: 1680-1684.
13. Benjamin J, Moldavsky S, Lee J, Rubin R, (2009) Prevalence of heparin-induced antibody in African-American hemodialysis patients-comparison to non-dialysis patients. Clin Nephrol 71: 263-266.
14. Nakamoto H, Shimada Y, Kanno T, Wanaka K, Matsuo T, et al. (2005) Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9Suppl 1: S2-7.
15. O'Shea S I, Lawson JH, Reddan D, Murphy M, Ortel TL, (2003) Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38: 541-548.
16. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, et al. (1984) Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 28: 47-55.
17. Warkentin TE, Sheppard JI, Moore JC, Kelton JG, (2010) The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 8: 216-218.
18. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG, (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6: 1304-1312.
19. McFarland J, Lochowicz A, Aster R, Chappell B, Curtis B, (2012) Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol 87: 776-781.
20. Aster RH (2010) Improving specificity in HIT testing. blood 116.
21. Palomo I, Pereira J, Alarcon M, Diaz G, Hidalgo P, et al. (2005) Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 19: 189-195.
22. Arepally GM, Ortel TL, (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355: 809-817.
23. Warkentin TE, Sheppard JAI, Moore JC, Moore KM, Sigouin CS, et al. (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? Journal of Laboratory and Clinical Medicine 146: 341-346.
24. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, et al. (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5: 1666-1673.
25. Warkentin TE, Sheppard JA, (2006) Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20: 259-272.
26. Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y, (2010) Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 103: 145-150.
27. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL, (2010) Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 116: 1761-1766.
28. Davenport A, (2009) Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis 54: 361-374.
29. Diaz J, Prechel M, Emanuele M, Emanuele N, Walenga JM, (2010) Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. Clin Appl Thromb Hemost 16: 121-125.
30. Martel N, Lee J, Wells PS, (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710-2715.
31. Matsuo T, Wanaka K, (2008) Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. Clin Appl Thromb Hemost 14: 459-464.
32. Ban-Hoefen M, Francis C, (2009) Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 124: 189-192.
33. Yu A, Jacobson SH, Bygden A, Egberg N, (2002) The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 40: 21-26.
34. Tsai YF, Chen CA, Kuo C, Lin KC, (2012) Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients. Clin Exp Nephrol 16: 300-305.
35. Inaba M, Hayashino Y, Shoji T, Akiba T, Akizawa T, et al. (2012) Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study. Nephron Clin Pract 120: c91-c100.
36. Canaud B, Tong L, Tentori F, Akiba T, Karaboyas A, et al. (2011) Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 6: 1651-1662.
37. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, et al. (2005) Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 45: 565-571.
38. Gruel Y, Lermusiaux P, Lang M, Darnige L, Rupin A, et al. (1991) Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann Vasc Surg 5: 552-555.
39. Kappa JR, Fisher CA, Addonizio VP Jr, (1989) Heparin-induced platelet activation: the role of thromboxane A2 synthesis and the extent of platelet granule release in two patients. J Vasc Surg 9: 574-579.
40. Greinacher A, Warkentin TE (2004) Treatment of heparin-induced thrombocytopenia: an overview. Heparin-induced thrombocytopenia, 3rd ed New York:Marcel Dekker: 335-370.
41. Bream-Rouwenhorst HR, Hobbs RA, Horwitz PA, (2008) Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation. J Interv Cardiol 21: 350-356.
42. Poncz M, (2005) Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 17: 73-79.
43. Kelton JG, (2005) The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 127: 9S-20S.